Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline (GSK) announced the 6-month primary treatment period results from the first Phase 3 study of oral migalastat HCl monotherapy in males and females with Fabry disease. The study did not achieve statistical significance according to the pre-specified primary endpoint analysis.
Amicus Therapeutics traded in a narrow range throughout Wednesday's session and finished up by 0.11 at $5.77. The stock is now down 2.80 on 637K shares after the bell.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org